Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Hannover Medical School

PharmaDeviceNews Hannover Medical School

Representative image of gene-editing research targeting inherited lung and liver disease as Serapha Bio’s SERP-01 restores protective alpha-1 antitrypsin protein levels in early clinical testing, showing promise for a one-time treatment.

Pharma & Biotech

SERP-01 gene-editing results support Phase 2/3 plans for inherited lung and liver disease

by Soujanya Ravi
October 26, 2026
0 Comments

Serapha Bio's SERP-01 gene editing restores protective protein levels in four AATD patients. Explore the early results and Phase 2/3 plans.

Read More

Latest news and features

SERP-01 gene-editing results support Phase 2/3 plans for inherited lung and liver disease
ORKA-001 shows strong psoriasis skin-clearance results as pivotal trials approach in 2027
Frontier’s FMC-376 triggered responses after KRAS inhibitor failure, but can its dual-state mechanism prevent resistance?
BeOne Medicines reports new Phase 1 results across three liver and lung cancer programmes
CatalYm’s visugromab lifted bladder cancer complete responses to 33%, but can it help patients avoid surgery?
Genmab and Incyte are combining three attacks on KRAS-mutant colorectal cancer, but can they overcome EGFR resistance?
Bayer reports 58% lower metastasis or death risk with NUBEQA in Phase 3 prostate cancer trial
AstraZeneca’s bladder cancer combination cut death risk by 42%, but can it compete with an approved rival regimen?
AstraZeneca and Amgen report 58% lower death risk with IMFINZI and tarlatamab in small-cell lung cancer
Pfizer’s new vaccine targets 25 pneumococcal serotypes, but can it outperform PREVNAR 20?
Genmab’s Rina-S slashed progression risk by 71%, but can it challenge ovarian cancer treatment standards?
Palleon Pharmaceuticals reports rapid remissions with HLX79/E-602 in Phase 2 kidney disease trial

POPULAR NEWS

Representative image of oncology biomarker testing and antibody-drug conjugate research. Antengene’s ATG-022 Phase III clearance highlights rising competition in CLDN18.2-targeted treatment for advanced gastric and gastroesophageal junction cancer.

Pharma & Biotech

Summit Therapeutics partners with Lunit to study AI tumor biomarkers for ivonescimab

October 24, 2026

Representative image of a clinician reviewing kidney cancer scans, reflecting Merck & Co., Inc.’s FDA approval of Keytruda and Welireg combinations for adjuvant clear cell renal cell carcinoma treatment.

Pharma & Biotech

Travere Therapeutics FILSPARI shows sustained biomarker reductions in Phase 3 PROTECT study

October 24, 2026

Representative image of researchers examining Alzheimer’s disease biomarker data as NeuroSense evaluates PrimeC’s multi-target potential in a small exploratory study.

Pharma & Biotech

NeuroSense links PrimeC to Alzheimer’s biomarkers, but can three patients justify another trial?

June 26, 2026

Latest business and industry news

Trump administration’s Alaska election lawsuit faces dismissal push as Senate certification dispute intensifies
Stryker expands orthopedic innovation strategy with completed ZuriMED deal
Tango Therapeutics targets pancreatic cancer market with Revolution Medicines combination as investors turn cautious
UN finds Russia committed crimes against humanity as Ukraine’s power grid attacks leave millions suffering
Brazilian Rare Earths expands Monte Alto resource by 41% as critical minerals development gains momentum

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.